Peel Hunt reissued their under review rating on shares of Shield Therapeutics (LON:STX) in a research note published on Friday, March 16th.
STX has been the topic of several other research reports. Liberum Capital reiterated an under review rating on shares of Shield Therapeutics in a research report on Monday, February 5th. FinnCap reiterated a buy rating and issued a GBX 265 ($3.72) target price on shares of Shield Therapeutics in a research report on Tuesday, November 21st.
Shares of LON STX traded up GBX 4 ($0.06) during trading on Friday, hitting GBX 19.50 ($0.27). The company had a trading volume of 265,219 shares, compared to its average volume of 48,665. Shield Therapeutics has a fifty-two week low of GBX 15 ($0.21) and a fifty-two week high of GBX 168.50 ($2.37).
ILLEGAL ACTIVITY NOTICE: “Shield Therapeutics’ (STX) Under Review Rating Reaffirmed at Peel Hunt” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/08/shield-therapeutics-stx-receives-under-review-rating-from-peel-hunt.html.
About Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on the development and commercialization of secondary care-focused pharmaceuticals. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its first pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.